Geode Capital Management
NEUP

Geode Capital Management’s Neuphoria Therapeutics NEUP Stock Holding History

Geode Capital Management’s Portfolio NEUP Stock Details NEUP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$212K Buy
52,007
+34,704
+201% +$147K ﹤0.01% 3891
2025
Q4 		$67.1K Buy
17,303
+4,325
+33% +$30.7K ﹤0.01% 4183
2025
Q3 		$153K Buy
+12,978
New +$120K ﹤0.01% 4015

Other funds holding NEUP

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.4% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return

Geode Capital Management's NEUP Position: Q1 2026 in Review

Geode Capital Management increased its Neuphoria Therapeutics (NEUP) stake by 201% in Q1 2026, buying an estimated $147K and bringing the position to 52,007 shares worth $212K. The position accounts for ﹤0.01% of the portfolio, ranked #3891.

Geode Capital Management first reported a position in NEUP in Q3 2025 and has held it in 3 quarters since. 19 funds tracked by Wall St. Rank hold NEUP as of Q1 2026.

  • Geode Capital Management held 52,007 shares of Neuphoria Therapeutics worth $212K as of Q1 2026.
  • Geode Capital Management bought 34,704 Neuphoria Therapeutics shares in Q1 2026, an estimated $147K.
  • Neuphoria Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3891 holding.
  • Geode Capital Management first reported a position in Neuphoria Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 19 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.